Vice President, Alliance Management and Corporate Development
CFO, Axis Therapeutics

Jacqueline Li Vice President, Alliance Management and Corporate Development CFO, Axis Therapeutics Jacqueline joined Athenex in 2017 to support the company’s strategic and operational objectives, including in respect of capital raising, business development, investor relations and project management. Jacqueline is also the CFO of Axis Therapeutics, a majority-owned subsidiary of Athenex principally engaged in the…

Vice President, Human Resources

John Matthei Vice President, Human Resources John has over 20 years of global human resources and operations management experience in the healthcare industry with a concentration in developing human resource competencies in high growth businesses. In his role at Athenex, John is responsible for providing overall leadership to the company’s global human resources organization and…

Vice President, Technical Operations, Cell Therapy

Jerrod Denham Vice President, Technical Operations, Cell Therapy  Mr. Jerrod Denham brings over two decades of experience developing cell and gene therapy products. He has provided strategic and technical CMC consultation for over 70 US and international cell and gene therapy clients, ranging from small private biotech companies to large public biotech companies and pharmaceutical…

Chief Business and Commercial Officer, Proprietary Drugs

Timothy Cook Chief Business and Commercial Officer, Proprietary Drugs Tim began his Oncology career with Bristol-Myers Squibb where he helped launch Taxol as an oncology sales professional. He held a variety of roles of increasing responsibility including Senior Director, Payer Marketing and Senior Director, Marketing. He joined Lilly Oncology in 2000. Among the roles Tim…

Deputy Chief Medical Officer, Biologics and Cell Therapy

David Cutler, MD, FRCP(C) Deputy Chief Medical Officer, Biologics and Cell Therapy David brings to Athenex significant scientific and managerial expertise in the field of translational pharmacology and clinical research. Prior to joining Athenex, David held leadership positions at Merck Research Laboratories and Schering-Plough Research Institute in the Department of Experimental Medicine. During his 30…

Chief Medical Officer, Cell Therapy

Darrel Cohen, MD, PhD Chief Medical Officer, Cell Therapy Dr. Cohen is a hematologist/oncologist with over 25 years of oncology clinical research and drug development experience in both solid tumors and hematological malignancies. He has held leadership positions of increasing responsibility at Pharmacia, Sanofi-Aventis, and Pfizer, including Vice President of Late-Phase Clinical Development at Pfizer…

Medical Officer, Small Molecules

Rudolf Kwan, MBBS, MRCP Medical Officer, Small Molecules Rudolf has had a successful career in the pharmaceutical industry with over twenty years of experience in global clinical development and operations. Before joining Athenex, he served dual roles at Schering-Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President…

Chief Financial Officer

Joe Annoni Chief Financial Officer Mr. Joe Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. Prior to joining Athenex, Mr. Annoni served as Managing Director with GFW Partners, a boutique advisory firm. Prior to GFW,…

President, Athenex Cell Therapy

Daniel Lang, MD President, Athenex Cell Therapy Dan brings to Athenex with over 25 years of medicine, healthcare investment as well as leadership and business experience. Prior to joining Athenex, Dan was the Chief Investment Officer of the RS Value franchise focused on domestic equity strategies. Dan was on the executive team of RS Investment…

Chief Operating Officer
President – Athenex Pharmaceutical Division

Jeffrey Yordon Chief Operating Officer President – Athenex Pharmaceutical Division Jeff has held multiple senior management positions in the pharmaceutical industry over the last 46 years. Jeff was the Founder, Chairman and CEO of Sagent Pharmaceuticals which had a market cap of $1.6 billion when he left the company in 2015. Prior to that, he…